Insider Trading Alert - OPK, ALGN, AREX, IBKR And MRK Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Nov. 1, 2013, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,920.00 to $142,506,400.00.

Highlighted Stocks Traded by Insiders:

Opko Health (OPK) - FREE Research Report

Frost Phillip Md Et Al who is CEO & Chairman at Opko Health bought 34,600 shares at $9.99 on Nov. 1, 2013. Following this transaction, the CEO & Chairman owned 136.9 million shares meaning that the stake was reduced by 0.03% with the 34,600 share transaction.

The shares most recently traded at $10.63, up $0.64, or 6.04% since the insider transaction.

The average volume for Opko Health has been 4.6 million shares per day over the past 30 days. Opko Health has a market cap of $4.0 billion and is part of the health care sector and health services industry. Shares are up 108.32% year to date as of the close of trading on Friday.

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. Currently there are 3 analysts that rate Opko Health a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OPK - FREE

TheStreet Quant Ratings rates Opko Health as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and feeble growth in the company's earnings per share. Get the full Opko Health Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Align Technology (ALGN) - FREE Research Report

Thaler Warren S who is Director at Align Technology sold 35,250 shares at $56.55 on Nov. 1, 2013. Following this transaction, the Director owned 140,484 shares meaning that the stake was reduced by 20.06% with the 35,250 share transaction.

Erfurth Jennifer who is VP, Global HR at Align Technology sold 3,242 shares at $56.97 on Nov. 1, 2013. Following this transaction, the VP, Global HR owned 3,080 shares meaning that the stake was reduced by 51.28% with the 3,242 share transaction.

The shares most recently traded at $58.29, up $1.32, or 2.26% since the insider transaction. Historical insider transactions for Align Technology go as follows:

  • 12-Week # shares sold: 10,977
  • 24-Week # shares sold: 35,083

The average volume for Align Technology has been 888,300 shares per day over the past 30 days. Align Technology has a market cap of $4.6 billion and is part of the health care sector and health services industry. Shares are up 105.62% year to date as of the close of trading on Friday.

Align Technology, Inc. operates as a medical device company primarily in the United States and internationally. The company has a P/E ratio of 150.2. Currently there are 5 analysts that rate Align Technology a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ALGN - FREE

TheStreet Quant Ratings rates Align Technology as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Align Technology Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Approach Resources (AREX) - FREE Research Report

Manoushagian Ralph P. who is EVP - Land at Approach Resources sold 722 shares at $28.06 on Nov. 1, 2013. Following this transaction, the EVP - Land owned 255,928 shares meaning that the stake was reduced by 0.28% with the 722 share transaction.

Smart Steven P. who is Evp & Cfo at Approach Resources sold 850 shares at $28.06 on Nov. 1, 2013. Following this transaction, the Evp & Cfo owned 332,074 shares meaning that the stake was reduced by 0.26% with the 850 share transaction.

Craft J. Ross who is President & CEO at Approach Resources sold 2,500 shares at $28.06 on Nov. 1, 2013. Following this transaction, the President & CEO owned 920,635 shares meaning that the stake was reduced by 0.27% with the 2,500 share transaction.

The shares most recently traded at $29.86, up $1.80, or 6.03% since the insider transaction. Historical insider transactions for Approach Resources go as follows:

  • 4-Week # shares sold: 22,960
  • 12-Week # shares sold: 31,104
  • 24-Week # shares sold: 69,248

The average volume for Approach Resources has been 643,000 shares per day over the past 30 days. Approach Resources has a market cap of $1.1 billion and is part of the basic materials sector and energy industry. Shares are up 12.55% year to date as of the close of trading on Friday.

Approach Resources Inc., an independent energy company, engages in the acquisition, development, exploration, and production of oil and gas properties in the United States. The company's properties are primarily located in the Permian Basin in West Texas, as well as in the East Texas Basin. The company has a P/E ratio of 351.9. Currently there are 11 analysts that rate Approach Resources a buy, 3 analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AREX - FREE

TheStreet Quant Ratings rates Approach Resources as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Approach Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Interactive Brokers Group (IBKR) - FREE Research Report

Galik Milan who is SVP Software Development at Interactive Brokers Group sold 2,000 shares at $20.78 on Nov. 1, 2013. Following this transaction, the SVP Software Development owned 763,604 shares meaning that the stake was reduced by 0.26% with the 2,000 share transaction.

The shares most recently traded at $21.12, up $0.34, or 1.61% since the insider transaction. Historical insider transactions for Interactive Brokers Group go as follows:

  • 4-Week # shares sold: 14,000
  • 12-Week # shares sold: 53,000
  • 24-Week # shares sold: 111,000

The average volume for Interactive Brokers Group has been 402,800 shares per day over the past 30 days. Interactive Brokers Group has a market cap of $1.0 billion and is part of the financial sector and financial services industry. Shares are up 50.91% year to date as of the close of trading on Friday.

Interactive Brokers Group, Inc. operates as an automated electronic broker and market maker. The stock currently has a dividend yield of 1.94%. The company has a P/E ratio of 24.0. Currently there are 4 analysts that rate Interactive Brokers Group a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on IBKR - FREE

TheStreet Quant Ratings rates Interactive Brokers Group as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, increase in net income, reasonable valuation levels and expanding profit margins. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Interactive Brokers Group Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Merck (MRK) - FREE Research Report

Cech Thomas R who is Director at Merck sold 500 shares at $45.13 on Nov. 1, 2013. Following this transaction, the Director owned 100 shares meaning that the stake was reduced by 83.33% with the 500 share transaction.

The shares most recently traded at $45.80, up $0.67, or 1.46% since the insider transaction.

The average volume for Merck has been 13.4 million shares per day over the past 30 days. Merck has a market cap of $132.0 billion and is part of the health care sector and drugs industry. Shares are up 10.48% year to date as of the close of trading on Friday.

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products worldwide. The stock currently has a dividend yield of 3.81%. The company has a P/E ratio of 15.5. Currently there are 5 analysts that rate Merck a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MRK - FREE

TheStreet Quant Ratings rates Merck as a buy. Among the primary strengths of the company is its expanding profit margins over time. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Merck Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Dow Jumps on Signs of Progress in U.S.-China Trade Discussions

Dow Jumps on Signs of Progress in U.S.-China Trade Discussions

Tax Loss Selling Recovery Candidates, Part 2

Tax Loss Selling Recovery Candidates, Part 2

Microsoft, Amazon, Apple Are Top Holdings of U.S. Hedge Funds

Microsoft, Amazon, Apple Are Top Holdings of U.S. Hedge Funds

Workday Has Been Working Higher on the Charts - More Gains to Come

Workday Has Been Working Higher on the Charts - More Gains to Come

American Eagle Shares Rise After Company Issues Weak Guidance

American Eagle Shares Rise After Company Issues Weak Guidance